Journal of Antimicrobial Chemotherapy (1999) 44, 835-838
© 1999 The British Society for Antimicrobial Chemotherapy
Brief report |
Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy
a Department of Thoracic Medicine, City Hospital, Birmingham, UK b Department of Medical Microbiology, City Hospital, Birmingham, UK
The concentrations of moxifloxacin achieved after a single 400 mg dose were measured in serum, epithelial lining fluid (ELF), alveolar macrophages (AM) and bronchial mucosa (BM). Concentrations were determined using a microbiological assay. Nineteen patients undergoing fibre-optic bronchoscopy were studied. Mean serum, ELF, AM and BM concentrations at 2.2, 12 and 24 h were as follows: 2.2 h: 3.2 mg/L, 20.7 mg/L, 56.7 mg/L, 5.4 mg/kg; 12 h: 1.1 mg/L, 5.9 mg/L, 54.1 mg/L, 2.0 mg/kg; 24 h: 0.5 mg/L, 3.6 mg/L, 35.9 mg/L, 1.1 mg/kg, respectively. These concentrations exceed the MIC90s for common respiratory pathogens such as Streptococcus pneumoniae (0.25 mg/L), Haemophilus influenzae (0.03 mg/L), Moraxella catarrhalis (0.12 mg/L), Chlamydia pneumoniae (0.12 mg/L) and Mycoplasma pneumoniae (0.12 mg/L) and indicate that moxifloxacin should be effective in the treatment of community-acquired, lower respiratory tract infections.
* Correspondence address. Department of Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham, B9 5SS, UK.
Tel: +44-121-766-6611; Fax: +44-121-772-0292; E-mail: davidhoneybourne{at}compuserve.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W S Lim, S V Baudouin, R C George, A T Hill, C Jamieson, I Le Jeune, J T Macfarlane, R C Read, H J Roberts, M L Levy, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009 Thorax, October 1, 2009; 64(Suppl_3): iii1 - iii55. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Brillault, W. V. De Castro, T. Harnois, A. Kitzis, J.-C. Olivier, and W. Couet P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1457 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-{kappa}B activation in a cystic fibrosis epithelial cell line Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L343 - L352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shalit, D. Halperin, D. Haite, A. Levitov, J. Romano, N. Osherov, and I. Fabian Anti-inflammatory effects of moxifloxacin on IL-8, IL-1{beta} and TNF-{alpha} secretion and NF{kappa}B and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus J. Antimicrob. Chemother., February 1, 2006; 57(2): 230 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ulrich, C. Albers, J.-G. Moller, A. Dalhoff, G. Korfmann, F. Kunkele, and G. Doring Moxifloxacin and Azithromycin but not Amoxicillin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae In Vitro when Administered up to 6 Hours after Challenge Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5119 - 5122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A. Groneberg, A. Fischer, K. F. Chung, and H. Daniel Molecular Mechanisms of Pulmonary Peptidomimetic Drug and Peptide Transport Am. J. Respir. Cell Mol. Biol., March 1, 2004; 30(3): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wilson, L. Allegra, G. Huchon, J.-L. Izquierdo, P. Jones, T. Schaberg, and P.-P. Sagnier Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis Chest, March 1, 2004; 125(3): 953 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Capitano, H. M. Mattoes, E. Shore, A. O'Brien, S. Braman, C. Sutherland, and D. P. Nicolau Steady-State Intrapulmonary Concentrations of Moxifloxacin, Levofloxacin, and Azithromycin in Older Adults Chest, March 1, 2004; 125(3): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Rodriguez, L. Cebrian, M. Lopez, M. Ruiz, I. Jimenez, and G. Royo Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis J. Antimicrob. Chemother., March 1, 2004; 53(3): 441 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leone, J. Albanese, E. Sampol-Manos, N. Simon, B. Lacarelle, B. Bruguerolle, and C. Martin Moxifloxacin Penetration in Bronchial Secretions of Mechanically Ventilated Patients with Pneumonia Antimicrob. Agents Chemother., February 1, 2004; 48(2): 638 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Drummond, D. L. Becker, M. Hux, J. V. M. Chancellor, I. Duprat-Lomon, R. Kubin, and P.-P. Sagnier An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia Chest, August 1, 2003; 124(2): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Danesi, A. Lupetti, C. Barbara, E. Ghelardi, A. Chella, T. Malizia, S. Senesi, C. A. Angeletti, M. Del Tacca, and M. Campa Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg J. Antimicrob. Chemother., April 1, 2003; 51(4): 939 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Giamarellos-Bourboulis, L. Karnesis, I. Galani, and H. Giamarellou In Vitro Killing Effect of Moxifloxacin on Clinical Isolates of Stenotrophomonas maltophilia Resistant to Trimethoprim-Sulfamethoxazole Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3997 - 3999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Rolain, M. Maurin, and D. Raoult Bacteriostatic and Bactericidal Activities of Moxifloxacin against Coxiella burnetii Antimicrob. Agents Chemother., January 1, 2001; 45(1): 301 - 302. [Abstract] [Full Text]
|
|
|
|
|
|
P. Petitpretz, P. Arvis, M. Marel, J. Moita, and J. Urueta Oral Moxifloxacin vs High-Dosage Amoxicillin in the Treatment of Mild-to-Moderate, Community-Acquired, Suspected Pneumococcal Pneumonia in Adults Chest, January 1, 2001; 119(1): 185 - 195. [Abstract] [Full Text] [PDF]
|
|